VENTANA MMR RxDx Panel
Ventana Medical Systems · Decision date Oct 8, 2026
What did the FDA approve?
FDA records P200019/S014 as a supplement to PMA P200019, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Oct 8, 2026.
FDA approval order statement
Approval to add a new anti-PMS2 clone, VENTANA anti-PMS2 (SP487) Rabbit Monoclonal Primary Antibody, to the VENTANA MMR RxDx Panel for use on the BenchMark ULTRA and BenchMark ULTRA PLUS platforms
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Pathology
- Decision date
- Oct 8, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P200019/S014
- Regulatory pathway
- PMA supplement
- Applicant
- Ventana Medical Systems
- Product code
- QNH
- Decision code
- APPR
- Decision date
- Oct 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay.
- Applicant
- Ventana Medical Systems
- Product code
- QNH
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200019. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200019 · Original PMA
VENTANA MMR RxDx Panel
P200019/S014 received
Application receipt date recorded by FDA.
P200019/S014 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P200019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VENTANA MMR RxDx PanelP200019 | Ventana Medical Systems | PMA approval | Apr 22, 2021 | FDA |
Explore the linked device profile
Other records with product code QNH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VENTANA MMR RxDx PanelP210001/S016 | Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) | PMA supplement | Oct 8, 2026 | FDA |
MMR IHC Panel pharmDx (Dako Omnis)P250004/S001 | Agilent Technologies, Inc. | PMA supplement | Sep 11, 2026 | FDA |
| Agilent Technologies, Inc. | PMA approval | Aug 15, 2025 | FDA | |
VENTANA MMR RxDx PanelP210001 | Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) | PMA approval | Aug 17, 2021 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ventana Medical Systems
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1910 E. Innovation Park Dr., Tucson, AZ, 85755
Sources and methodology
- Original FDA record: P200019/S014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


